INTRODUCTION
Early life respiratory infections with certain bacteria and viruses such as Chlamydia and Mycoplasma and respiratory syncytial virus (RSV) and influenza, respectively, are linked to the development of chronic lung disease. [1] [2] [3] [4] Evidence from clinical and more recently animal model studies link early-life Chlamydia respiratory infection with the development of impaired lung structure and function. 3, [5] [6] [7] In humans, Chlamydia pneumoniae and Chlamydia trachomatis are common respiratory pathogens, particularly in early life. Antibodies to C. pneumoniae are found in 50-80% of adults, and this bacterium is a frequent cause of childhood and community-acquired pneumonia.
1 C. trachomatis is a common infection of the female reproductive tract and the incidence of vertical transmission to the respiratory tracts of newborns is reported to be as high as 60%, with up to 16% developing pneumonia. 8 Chlamydia respiratory infections in early life, particularly those with C. pneumoniae, have been associated with the development of asthma 1, 9 and up to 46% of pediatric patients with asthma have detectable Chlamydia in their lungs. 10, 11 We have recently demonstrated that neonatal respiratory infection with the natural mouse respiratory pathogen Chlamydia muridarum leads to emphysema-like alveolar enlargement and persistent airway hyperresponsiveness (AHR), 3, 12 which has been confirmed by others. 6 However, the immunological and inflammatory pathways that are responsible for predisposing to the long-term sequelae of early-life respiratory infection remain unknown.
Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL; also known as tumor necrosis factor ligand, superfamily member 10 (TNFSF10)) is an immune factor that regulates both inflammation and apoptosis. 13 It was identified based on its sequence homology to Fas ligand and tumor necrosis factor.
14 TRAIL is expressed by a variety of cells including epithelial cells, monocytes/macrophages, neutrophils, dendritic cells, and T cells. [15] [16] [17] [18] [19] [20] Four cell surface receptors for TRAIL have been identified; death receptor 4 (DR4; also known as TRAIL-R1), DR5 (TRAIL-R2), decoy receptor 1 (DcR1; also know as TRAIL-R3) and DcR2 (TRAIL-R4). [21] [22] [23] [24] Both DR4 and DR5 have functional death domains that signal for apoptosis; however, in mice, DR5 is the only apoptosisinducing TRAIL receptor. DcR1 and DcR2 are expressed in both humans and mice and have no or truncated death domains, respectively, and therefore their activation does not lead to apoptosis. Notably, stimulation of DR4, DR5, and DcR2 can induce activation of NF-kB, which promotes inflammatory and immune responses. 21, 25 TRAIL is important in the immune response to early-life respiratory viral infections including RSV and influenza, which upregulate TRAIL and its receptors, and these viral infections have been linked to persistent pulmonary dysfunction. 4, 16, 18, [26] [27] [28] TRAIL-induced responses are known to promote pulmonary inflammation, mucus hypersecretion, apoptosis of airway epithelial cells, and AHR. 15, 17, 29 However, its role in early-life respiratory infection and in driving infection-induced chronic lung disease is unknown.
In the present study, we demonstrate that TRAIL has a previously unrecognized role in promoting neonatal Chlamydia respiratory infection and is pivotal in infection-induced histopathology, inflammation, alveolar enlargement, and persistent AHR. This identifies TRAIL and its receptors as novel therapeutic targets for respiratory Chlamydia infections in early life and for the prevention of infection-induced chronic lung disease.
RESULTS

The absence of TRAIL results in reduced neonatal
Chlamydia respiratory infection-induced histopathology and mucus hypersecretion
To investigate the role of TRAIL during neonatal Chlamydia respiratory infection, wild type (WT) and Tnfsf10 À / À BALB/c mice were infected intranasally (i.n.) with the natural mouse pathogen C. muridarum within 24 h of birth, and weight gain and Chlamydia load in the lungs were assessed. Infection of WT mice resulted in significantly reduced weight gain from 8 days post infection (d.p.i.) compared with sham-inoculated WT (sham WT) controls (Figure 1a) . In contrast, infection of Tnfsf10 À / À mice did not result in reduced weight gain compared with shaminoculated Tnfsf10 À / À controls and weight gain was returned to normal (i.e., that of sham-inoculated WT controls). In WT mice, there was an increase in Chlamydia load at 5 d.p.i., infection peaked at 10 d.p.i., and there was a significant decrease at 15 d.p.i. and a further reduction at 20 d.p.i. (Figure 1b) . Infection in Tnfsf10 À / À mice did not result in significantly different Chlamydia load to that in WT (C. muridarum WT) controls at 5, 10 or 15 d.p.i., although infection was slightly but significantly decreased at 20 d.p.i.
We have previously shown that histopathology (the major determinant of which is pulmonary inflammation) peaks at 15 d.p.i. in neonatal WT mice 12 and therefore, this is the optimal time point to assess this consequence of infection. Infection of WT mice resulted in significant increases in both histopathology and MSC numbers in the airways at 15 d.p.i. (Figures 1c and d (Figures 2a-g ).
Neonatal Chlamydia respiratory infection increases TRAIL production and DR5 expression in the lung As infection-induced histopathology and inflammation were reduced in Tnfsf10 À / À mice, the effect of infection on TRAIL production and TRAIL receptor expression was assessed. Infection of WT mice resulted in significantly increased TRAIL messenger RNA (mRNA) expression in the lung at 15 d.p.i., but not at 5, 10 or 20 d.p.i., compared with sham-inoculated controls (Figure 3a) . There was a concomitant increase in the production of TRAIL protein (Figure 3b) . Infection increased both the percentage of epithelial cells and alveolar macrophages and the total number of epithelial cells, alveolar macrophages, and inflammatory monocytes expressing TRAIL at 15 d.p.i. (Figures 3c and d (Figure 3e) . No change in DcR1 or DcR2 mRNA expression was observed at any time point (Figures 3f and g ).
Neonatal Chlamydia respiratory infection-induced DR5 expression and apoptosis, which is associated with alveolar enlargement
We have previously shown that infection of neonatal WT BALB/c mice results in alveolar enlargement that persists into ARTICLES MucosalImmunology | VOLUME 7 NUMBER 3 | MAY 2014 adulthood, 3 and this has been recently supported by the studies of others. 6 Here we confirm this observation and show that the infection of neonatal WT mice results in significantly enlarged alveoli at 61 d.p.i., compared with sham-inoculated WT controls (Figure 4a) . By contrast, infection of neonatal Tnfsf10 À / À mice had no effect on alveolar size, compared with sham-inoculated Tnfsf10 À / À controls. Thus, significantly, infected Tnfsf10
mice are protected against infection-induced alveolar enlargement, with alveolar diameter returned to baseline (i.e., to that of sham-inoculated WT controls). We next sought to determine if differences in DR5 expression and apoptosis were associated with alveolar enlargement in infected WT and Tnfsf10 À / À mice. In WT mice, TRAIL and DR5 mRNA were upregulated at 15 d.p.i. (Figures 3a and b) , so we assessed DR5 expression and apoptosis of lung epithelial and endothelial cells at this time point. Infection of both neonatal WT and Tnfsf10
À / À mice resulted in increased DR5-positive epithelial (T1a þ ) and endothelial (CD31 þ ) cells in the lung at 15 d.p.i. (Figure 4b ).
This was associated with a significant increase in epithelial and endothelial cell apoptosis in infected WT mice (Figure 4c) . However, infection of neonatal Tnfsf10 À / À mice did not induce apoptosis of lung epithelial or endothelial cells, compared with sham-inoculated (sham Tnfsf10 À / À ) controls. We next investigated whether infection was required for alveolar enlargement by administering recombinant (r) TRAIL or agonistic anti-DR5 antibody to the lungs of naïve neonatal WT mice (day 0-18) in the absence of infection. Stimulation of these pathways during early life in the absence of infection had no effect on alveolar size in later life (day 61), compared with isotype-treated controls ( Figure 4d ).
Neonatal Chlamydia respiratory infection promotes persistent AHR in a TRAIL-dependent manner
We have previously shown that neonatal Chlamydia respiratory infection results in persistent AHR in mice characterized by increased transpulmonary resistance and decreased dynamic compliance in response to methacholine. 3, 12 Here we confirm this observation and show that infection of neonatal WT mice significantly increased AHR, compared with shaminoculated WT controls (Figures 5a and b) . By contrast, and importantly, infected Tnfsf10 À / À mice did not develop AHR, as measurements of transpulmonary resistance and dynamic compliance in response to methacholine were not significantly different from sham-inoculated Tnfsf10 À / À controls and were returned to baseline (i.e., to that of sham-inoculated WT controls).
To determine whether it was the infection or increases in TRAIL or DR5 that was required for induction of persistent AHR, rTRAIL, or agonistic anti-DR5 antibody was administered into the lung of neonatal WT mice in the absence of infection (day 0-18). Importantly, exogenous TRAIL or stimulation of DR5 during early life, in the absence of infection, had no significant effect on AHR in later life (day 61) compared with isotype-treated controls (Figures 5c and d, and Supplementary Figures S1a-h online).
Blockade of DcR2 during neonatal Chlamydia respiratory infection reduces histopathology, NF-jB activation, and AHR
We then assessed the role of the TRAIL decoy receptors DcR1 and DcR2 in Chlamydia respiratory infection and infectioninduced pathology. Infected WT mice were treated with blocking antibodies against DcR1 or DcR2 throughout the course of infection. Blockade of DcR1 or DcR2 had no effect on Chlamydia load, MSC numbers around the airways, or the activity of RelB, p65, and p50 at 15 d. (Figure 1) . Therefore, in order to assess the potential of targeting TRAIL therapeutically, WT neonatal mice were treated with neutralizing anti-TRAIL antibody from 8-18 d.p.i., and the effect on Chlamydia load, histopathology, mucus hypersecretion, lung structure, and AHR were assessed. Neutralization of TRAIL did not have a significant effect on Chlamydia load at 10 or 15 d.p.i. (Figure 7a ), but significantly reduced histopathology and MSC numbers around the airways at 15 d.p.i. compared with infected isotype-treated controls (Figures 7b and c) . Importantly, neutralization of TRAIL also effectively reduced the consequences of early-life infection in adulthood, preventing infection-induced alveolar enlargement, and persistent AHR (decreased transpulmonary resistance and increasing dynamic compliance in response to methacholine) at 61 d.p.i. (Figures 7d and f) .
DISCUSSION
In this study, we discovered a previously unrecognized role for TRAIL in the immune response to early-life Chlamydia respiratory infection that predisposes to acute and chronic pathology. Using a combination of TRAIL-deficient mice and neutralizing antibodies that target TRAIL or its receptors, we demonstrate that TRAIL promotes clinical signs (weight loss), and infection-induced histopathology, inflammation, mucus hypersecretion, alveolar enlargement, and AHR. Most importantly, therapeutic targeting of TRAIL during infection decreases these sequelae of infection. Our study further highlights the emerging role of TRAIL in the immune response to respiratory infections.
In our study, we used C. muridarum, as this is a natural mouse pathogen and it requires low-level inocula to induce a productive infection, which replicates the infectious, immunological, and pathological progression of disease in humans, as we have previously published. 1, 12 It is therefore the most appropriate strain to use to study host-pathogen relationships in mice. In contrast, the human pathogen C. pneumoniae requires a large challenge dose to induce an immune response and does not form a productive infection in mice. Thus, these are clearances rather than infection models and do not replicate what is observed in humans.
Infected Tnfsf10 À / À mice had normal weight gain during neonatal Chlamydia respiratory infection, which correlated with reduced histopathology, mucus hypersecretion, and infiltration of inflammatory monocytes, mDCs, and CD4 þ and CD8
þ T cells into the lung. This is in contrast to infected WT mice, which displayed reduced weight gain, and increased histopathology, mucus hypersecretion, and infiltration of all major inflammatory leukocyte subsets examined into the lung. These observations expand on our previous studies, which show that TRAIL drives inflammation and mucus hypersecretion in non-infectious settings. 15 Intranasal administration of rTRAIL to naïve adult BALB/c mice increased the number of mDCs and CD4 þ T cells in the lung and promoted MSC hypersecretion. 15 Furthermore, the use of Tnfsf10 À / À mice and silencing of TRAIL using specific small interfering RNA (siRNA) decreased pulmonary inflammation and MSC numbers during ovalbumin-induced allergic airway disease (AAD).
15 Surprisingly, the absence of TRAIL had minimal effects on Chlamydia load, with a small but significant decrease in the bacterial burden observed only at 20 d.p.i.. Thus, we propose that the major impact of TRAIL is on immune responses to Chlamydia and in the sequelae of infection rather than on the infection itself. Our observations are in contrast to respiratory pneumococcal infection in adult C57BL/6 mice, where TRAIL deficiency lead to more severe infection and increased mortality. 30 This suggests that TRAIL may have a protective role in pneumococcal pneumonia.
Interestingly, following neonatal Chlamydia respiratory infection, there was a concomitant increase in TRAIL mRNA expression and protein levels in the lung that correlated with the peak of inflammation. We identified T1a þ epithelial cells and macrophages/monocytes as the major sources of cell surfacebound TRAIL in the lung. We have previously shown that the airway epithelium was a dominant source of TRAIL during AAD, 15 and others have shown that macrophages expressing TRAIL are important in influenza-induced alveolar leakage and 
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MucosalImmunology | VOLUME 7 NUMBER 3 | MAY 2014 related mortality. 17 Chlamydia can infect both epithelial cells and macrophages, 31, 32 and infection of these cells may increase the expression TRAIL. Additionally, Chlamydia-induced type I interferons may induce the expression of TRAIL in the lung. 33 Furthermore, infection-induced infiltration of inflammatory monocytes expressing TRAIL may also contribute to TRAILdependent pathology. While TRAIL expression on the cell surface of neutrophils in our model was negligible, these cells have been shown to be a major source of secreted TRAIL in a mouse model of pneumococcal pneumonia. 30 Thus, it is possible that neutrophils may also contribute to the increased levels of TRAIL in the lung following neonatal Chlamydia respiratory infection. Others have also shown that T cells express TRAIL on their cell surface following viral infection. 16 However, Chlamydia, unlike respiratory viruses, induces negligible TRAIL expression on CD4 þ and CD8 þ T cells. Another explanation is that neonatal (as opposed to adult) T cells may not increase their expression of TRAIL in response to infection. This may help to limit apoptosis following T-cell driven immune responses, which may be important in the growth of the developing lung.
We have previously shown that neonatal, but not infant or adult, Chlamydia respiratory infection leads to emphysemalike alveolar enlargement that persists into adulthood, 3 which has recently been confirmed by others. 6 In this study, we demonstrate the mechanism involved. We show that the infection induces the upregulation of DR5 on T1a þ lung epithelial and CD31 þ cells, which were probably endothelial cells, and others have shown that increases in this receptor sensitizes these structural cells to TRAIL-induced apoptosis.
27
CD31 is the most commonly used endothelial cell marker, although other cells such as macrophages and neutrophils can also express CD31. Tnfsf10 À / À mice had increased DR5 expression on epithelial and endothelial cells, but in the absence of TRAIL, the number of epithelial cells that were apoptotic was reduced back to baseline. These data indicate that TRAIL is not required for infection-induced upregulation of DR5 on epithelial and endothelial cells but that it is responsible for infection-induced epithelial cell apoptosis. We observed increased number of apoptotic CD31 þ cells in infected WT mice, so it is possible that apoptosis of CD31 þ endothelial cells may contribute to alveolar enlargement. However, there was not a significant decrease in infected Tnfsf10 À / À mice, so we cannot definitively conclude that TRAIL is inducing apoptosis of endothelial cells. Infection also increased the amount of TRAIL and the number of TRAIL-expressing cells (namely epithelial cells, alveolar macrophages, and inflammatory monocytes), which may bind to DR5 þ epithelial cells to induce apoptosis. Importantly, administration of rTRAIL or agonistic anti-DR5 antibody to naïve neonatal WT mice (day 0-18) in the absence of infection did not induce alveolar enlargement in later life (day 61) demonstrating that infection-induced upregulation of DR5 expression is required for TRAIL-induced apoptosis. Collectively, these data suggest that concomitant infection-induced increases in both TRAIL and DR5 promote TRAIL-induced apoptosis of lung epithelial cells during early life. This may impair normal alveolar development and lead to emphysemalike alveolar enlargement in later life.
Our observations may be broadly applicable to other pathogenic respiratory infections in early life. RSV strongly upregulates TRAIL and its functional receptors DR4 and DR5 in normal human primary bronchial epithelial and small airway epithelial cells 27 and in primary bronchial epithelial cells from children. 34 Increased levels of soluble TRAIL were found in the bronchoalveolar lavage fluid of children with severe RSV infection, 34 and up to 11% of children with RSV infection develop infantile lobar emphysema. 35, 36 However, a link between alveolar enlargement and TRAIL in RSV has not been made. Influenza (H1N1, A/PR/8/34) infection of mice upregulates TRAIL expression on natural killer cells, CD8
þ T cells and inflammatory monocytes and DR5 on infected T1a þ alveolar epithelial cells. 16, 17, 26 Importantly, influenza infections in early life also promote emphysema-like alveolar enlargement that persists in adulthood, 4 although the role of TRAIL in this process has not been investigated. Therefore, it is unlikely that our observations are restricted only to Chlamydia respiratory infections.
We have previously shown that neonatal and infant, but not adult, Chlamydia respiratory infection promotes the development of persistent AHR (increased transpulmonary resistance and decreased dynamic compliance in response to methacholine) in the absence of antigen sensitization or challenge, 3, 12, 37 which has been confirmed by others. 6 Here we also demonstrate the mechanisms involved in this observation. We have made the discovery that in the absence of TRAIL, infectioninduced AHR was completely ablated. We also demonstrate that administration of rTRAIL or agonistic anti-DR5 antibody to the lungs of naïve neonatal BALB/c mice (from day 0-18) had no effect on the development of persistent AHR (day 61). These data suggest that infection-induced persistent AHR is dependent on TRAIL. We have previously shown that TRAIL and TRAIL responses are pivotal in driving AHR in adult models of AAD. 15, 29 TRAIL deficiency and silencing of TRAIL with specific siRNA abolished ovalbumin-induced AHR during AAD. 15 Moreover, delivery of rTRAIL into the airways of naïve adult WT mice induced acute AHR within 24 h of administration. 15 This is in contrast to our observation, which can be explained by the fact that rTRAIL administration in our model ceased 6 weeks prior to assessment of AHR. In our current study, we demonstrate that during infection, TRAIL signals through DcR2 to induce persistent AHR. The expression of TRAIL was increased by infection, although that of DcR2 was not. Nevertheless, the increase in TRAIL may drive increased DcR2 signaling. In support of this, blockade of DcR2, but not DcR1, during infection prevented the infection-induced increase in transpulmonary resistance in later life. DcR2 is known to activate NF-kB, 21 which has been implicated in pulmonary inflammation and AHR. 38 Using a transgenic mouse model in which activation of NF-kB occurred only in the airway epithelium, Pantano et al., 38 demonstrated that activation of NF-kB was sufficient to induce AHR in the absence of antigen sensitization and challenge. We demonstrate that blockade of DcR2 during infection significantly decreased NF-kB (p52) activity in the lungs. We have also recently shown that TRAIL induces the expression of the E3 ubiquitin ligase midline-1 (MID1) in the airway wall and that siRNA-induced knockdown of MID1 reduces NF-kB activity in a house dust mite model of AAD and in an RV infection model. 29 Thus, we propose that infection-induced TRAIL signals through DcR2 and potentially MID1 and NF-kB-mediated pathways in airway epithelial cells to promote infection-induced persistent AHR. Importantly, this is the first in vivo study to use anti-DcR1 and anti-DcR2-blocking antibodies.
Finally, and most importantly, neutralization of TRAIL from 8 d.p.i. reduced Chlamydia infection-induced histopathology and mucus hypersecretion, and prevented the development of alveolar enlargement and persistent AHR; however, Chlamydia load was unaffected. These data suggest that infection-induced pathology is independent of bacterial load, but dependent on infection-induced TRAIL responses. Thus, treatment of neonates presenting with Chlamydia or other respiratory infections with antibiotics or antivirals may be of limited efficacy, as the induction of TRAIL-mediated responses occur concurrently with the development of infection-related symptoms. However, early intervention of 'at risk' neonates with antibiotics and antivirals may be beneficial. Others have shown that administration of erythromycin every 12 h for 3 consecutive days from 2 d.p.i., protected against neonatal Chlamydia respiratory infection-induced alveolar enlargement, but had minimal effects on AHR. 6 Nevertheless, clinical signs (i.e., reduced weight gain) do not become apparent until during infection and more generalized approaches may have broader applicability. Thus, targeting of TRAIL, its receptors, and signaling pathways, may be of widespread therapeutic relevance to early-life respiratory infections and in preventing chronic lung disease.
In summary, our study reveals for the first time that TRAIL promotes the long-term consequences of neonatal Chlamydia respiratory infection and is pivotal in promoting histopathology, inflammation, mucus hypersecretion, alveolar enlargement, and persistent AHR. Chlamydia respiratory infection sensitizes lung epithelial cells to TRAIL-induced apoptosis, which facilitates the development of emphysema-like changes in the lung. Furthermore, TRAIL promotes AHR via DcR2-dependent signaling pathways. Collectively, our data suggest that therapeutic targeting of infection-induced TRAIL and TRAIL receptors may be beneficial in reducing the severity of early-life respiratory infection-induced pathology and in preventing the development of associated chronic lung disease. Chlamydia load. Total DNA was isolated from lung homogenates using SurePrep RNA/DNA/Protein Purification kits (Fisher Bioreagents, Scoresby, Victoria, Australia) according to manufacturer's instructions. Chlamydia numbers were determined by real-time quantitative, by comparing to standards of known concentration (inclusion-forming units) of C. muridarum as previously described. 3, 12, 36, 40, 41 Histopathology. Lungs were formalin-fixed, embedded, and sectioned (4-6 mm). Transverse sections were stained with hematoxylin and eosin (for histopathology) and periodic acid-Schiff (for mucussecreting cells). Histopathology was scored according to a set of custom-designed criteria ( Table 1) 12 and MSCs were enumerated in inflamed airways as previously described. [42] [43] [44] Flow cytometry. Single-cell suspensions of collagenase-D-digested lungs were prepared and total cell numbers enumerated by trypan blue exclusion. Cells were incubated with mouse FcgII/III block (BD Biosciences, North Ryde, New South Wales, Australia) for 15 min to prevent non-specific immunofluorescent staining. In optimization experiments, test antibodies were compared with their isotype controls. No significant non-specific staining was identified with isotype controls at the concentration used compared with unstained controls during these experiments. Blocked cells were stained for the surface markers CD3, CD4, CD8, F4/80, CD11c, CD11b, Gr-1, T1a, CD31, TRAIL, and DR5 (Biolegend, Karrinyup, Western Australia, Australia) and PDCA (Miltenyi, North Ryde, New South Wales, Australia). Apoptotic cells were quantified using an FITC annexin-V dead cell apoptosis kit (Invitrogen, Mount Waverely, Victoria, Australia). Cells were fixed with 4% paraformaldehyde and cell populations analyzed using FACSCanto and FACSDiva software (BD Biosciences). 37, 40, 45, 46 Inflammatory cells subsets were defined as described in Table 2 and representative gating strategies are shown in Supplementary Figures 2-7 .
Enzyme-linked immunosorbent assay. Total protein was isolated from lung homogenates using SurePrep RNA/DNA/Protein Purification kits. Purified total protein was quantified using BCA Protein Assay Kits (PIERCE, Scoresby, Victoria, Australia) according to manufacturer's instructions. The concentration of murine TRAIL in lung homogenates was analyzed by ELISA using paired antibodies (R&D systems, Gymea, New South Wales, Australia). 15 NF-kB subunit (p52, RelB, p65, and p50) activity was determined using the NF-kB family transcription factor assay kit (Active Motif, Carlsbad, CA) according to the manufacturer's instructions. 29 Quantification of mRNA expression by real-time quantitative PCR.
Total RNA was isolated from lung homogenates using SurePrep RNA/ DNA/Protein Purification kits. 37 Extracted RNA was treated with DNAseI (Sigma-Aldrich, Castle Hill, New South Wales, Australia) and reverse-transcribed using Bioscript (Bioline, Alexandria, New South Wales, Australia) and random hexamer primers (Invitrogen). Relative abundance of cytokine cDNA was determined by comparison with the reference gene hypoxanthine-guanine phosphoribosyltransferase by real-time PCR using an Eppendorf RealPlex 2 System (Eppendorf, North Ryde, New South Wales, Australia). Custom-designed primers (IDT, Coralville, IA) were used for the analysis of mRNA expression for TRAIL (For; Lung function. Lung function, in terms of AHR, was measured in anesthetized mice using invasive whole-body plethysmography (Buxco, Wilmington, NC) by determination of transpulmonary 
þ mDC, myeloid dendritic cell, pDC, plasmacytoid dendritic cell.
resistance and dynamic compliance in response to increasing doses of nebulized methacholine (Sigma) at 61 d.p.i. [47] [48] [49] Alveolar enlargement. Average alveolar diameter was evaluated at 61 d.p.i. by determination of the mean linear intercept.
3,50
In vivo administration of rTRAIL, agonistic anti-DR5, and antiDcR1, and anti-DcR2-blocking antibodies. WT mice were treated with 0.5 mg g À 1 body weight of murine rTRAIL (R&D systems), agonistic anti-DR5 antibody (MD5-1), and neutralizing anti-DcR1 antibody (mDcR1-3), or anti-DcR2 antibody (mDcR2-1) i.n. 0, 3, 6, 9, 12, 15, and 18 d.p.i. 15 Sham-treated controls received sterile PBS or isotype control i.n.
In vivo neutralization of TRAIL. WT mice were treated with neutralizing anti-TRAIL antibody (N2B2) or isotype control (12.5 mg g À 1 body weight i.p.) every second day from day 8-18. 51, 52 Statistics. Results are represented as±s.e.m., which is representative of 2-3 independent experiments with each experimental iteration consisting of at least three mice. Statistical significance for multiple comparisons was determined by one-way analysis of variance with Bonferroni post test, or non-parametric equivalent, where appropriate using GraphPad Prism Software version 5 (San Diego, CA).
